Search | Clinical Trials Finder

Conditions: Crohn Disease
Interventions: infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Biological · Other · Drug
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more

Conditions: Urinary Incontinence
Interventions: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark); Device
Lead sponsor: Copenhagen University Hospital at Herlev; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoarthritis, Knee
Interventions: Traumeel® / Zeel® Injectable Solution, Placebo; Drug
Lead sponsor: Biologische Heilmittel Heel GmbH; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more

Conditions: Colitis, Ulcerative
Interventions: Delayed and extended release mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tobacco Dependence
Interventions: Nicotine Patch, Nicotine Gum; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 13 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions: FEP-TAZ 4 g, Placebo; Drug · Other
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions: PQ Grass, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more

Conditions: Brain Tumor
Interventions: Bright Light Exposure, Dim Light Exposure, Cognitive Assessment; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Hylenex; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Dry Eye Syndromes
Interventions: CP-690,550, Cyclosporine, CP-690,550 Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Placebo, Omega-3, Yoga, Exercise, Usual Activity; Dietary Supplement · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Irritable Bowel Syndrome
Interventions: Rimegepant 75 MG [Nurtec]; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions: branebrutinib, abatacept, branebrutinib placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Covina, California • Encino, California + 35 more

Conditions: Celiac Disease
Interventions: DONQ52, Placebo; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 18
States / cities: Anniston, Alabama • Denver, Colorado • Jacksonville, Florida + 15 more

Conditions: Alzheimer Disease
Interventions: Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more

Conditions: Knee Osteoarthritis
Interventions: Liposomal bupivacaine, Ropivacaine, Epinephrine, Clonidine, Saline; Drug
Lead sponsor: The Hawkins Foundation; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Autism, Autism Spectrum Disorder, ASD
Interventions: Vasopressin (USP) Injectable Solution [Vasostrict], Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Basal Cell Carcinoma
Interventions: Doxorubicin-containing MNA, Placebo-containing MNA; Combination Product · Drug
Lead sponsor: SkinJect, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: West Palm Beach, Florida • New York, New York

Conditions: Parkinson's Disease, Essential Tremor, Dystonia
Interventions: Dexmedetomidine Hydrochloride Infusion, Normal Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 12 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Bullous Pemphigoid
Interventions: dupilumab, Matching Placebo, Oral corticosteroids (OCS); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more

Conditions: Systemic Sclerosis-associated Interstitial Lung Disease
Interventions: Abituzumab 1500 mg, Abituzumab 500 mg, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions: Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol); Drug
Lead sponsor: Steven E Harte, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Systematic Light Exposure in Pediatric Brain Tumor Survivors

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

Comparison of Rimegepant and Placebo for Pain in IBS

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Exparel vs Exparel Plus ACB in TKAs

Intranasal Vasopressin Treatment in Children With Autism

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Abituzumab in SSc-ILD

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee